Suppr超能文献

人分泌型和胞质型磷脂酶A2的差异抑制作用

Differential inhibition of human secretory and cytosolic phospholipase A2.

作者信息

Märki F, Breitenstein W, Beriger E, Bernasconi R, Caravatti G, Francis J E, Paioni R, Wehrli H U, Wiederkehr R

机构信息

Research Department, Ciba-Geigy Limited, Basel, Switzerland.

出版信息

Agents Actions. 1993 Mar;38(3-4):202-11. doi: 10.1007/BF01976212.

Abstract

The roles and relative contributions of secretory and cytosolic phospholipases A2 in physiology and pathology are not precisely known. In a search for differential inhibitors of these enzymes, which could serve as tools to clarify this issue, we evaluated the potencies of reference compounds and three series of new compounds, viz. substrate analogues, 1,2-amino alcohols and enolized beta-tricarbonyl derivatives, as inhibitors of secretory phospholipase A2 from human polymorphonuclear leukocytes (sPLA2) and of cytosolic phospholipase A2 from human U937 cells (cPLA2). With few exceptions, the compounds selected are potent inhibitors of sPLA2 with IC50 values (concentration inhibiting 50%) in the low micromolar range. Inhibition of cPLA2 was only observed with some phosphate-free substrate analogues, with 1,2-amino alcohols and two of seven reference compounds. These results suggest that inhibition of secretory and of cytosolic phospholipases A2 are independent effects. Several inhibitors could be identified with a marked selectivity for sPLA2.

摘要

分泌型和胞质型磷脂酶A2在生理和病理过程中的作用及相对贡献尚不完全清楚。为了寻找这些酶的差异抑制剂,以便作为阐明这一问题的工具,我们评估了参考化合物以及三个系列新化合物,即底物类似物、1,2-氨基醇和烯醇化β-三羰基衍生物,作为人多形核白细胞分泌型磷脂酶A2(sPLA2)和人U937细胞胞质型磷脂酶A2(cPLA2)抑制剂的效力。除少数例外,所选化合物是sPLA2的有效抑制剂,其IC50值(抑制50%的浓度)在低微摩尔范围内。仅在一些无磷酸盐的底物类似物、1,2-氨基醇和七种参考化合物中的两种中观察到对cPLA2的抑制作用。这些结果表明,对分泌型和胞质型磷脂酶A2的抑制是独立的效应。可以鉴定出几种对sPLA2具有显著选择性的抑制剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验